[The detection of minimal residual disease by DEK/CAN chimeric m-RNA in a case of AML M2 with translocation t(6;9) (p23;q34) after chemotherapy and peripheral blood stem cell transplantation].

Abstract	A 18-year old female with acute myelogenous leukemia (AML), M2 had translocation: t(6;9) (p23; q34). The patient entered into hematological complete remission after two courses of BHAC-DMP chemotherapy with disappearance of cytogenetic abnormality. However, minimal residual disease (MRD) detected with DEK/CAN chimeric m-RNA by reverse transcription polymerase chain reaction (RT-PCR) was continuously observed, although decreased quantitatively, following several courses of consolidation and intensification chemotherapies. MRD was detected also in the harvested peripheral blood stem cells (PBSC). Leukemia relapsed with the reappearance of t(6;9) 2 months after the subsequent peripheral blood stem cell transplantation (PBSCT). Leukemia became refractory to chemotherapy, and the patient died 5 months thereafter.
Authors	M Toyosawa, K Shinohara, K Ariyoshi, T Ando, M Kobayashi, K Hikiji
Journal	[Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 38 Issue 1 Pg. 33-40 (Jan 1997) ISSN: 0485-1439 [Print] Japan
PMID	9028159 (Publication Type: Case Reports, Journal Article)
Chemical References	DEK-CAN fusion protein, recombinant Oncogene Proteins Oncogene Proteins, Fusion RNA, Messenger Recombinant Fusion Proteins Cytarabine Etoposide Prednisolone Mitoxantrone Mercaptopurine Daunorubicin
Topics	Adolescent Antineoplastic Combined Chemotherapy Protocols (therapeutic use) Chromosomes, Human, Pair 6 Chromosomes, Human, Pair 9 Combined Modality Therapy Cytarabine (administration & dosage, analogs & derivatives) Daunorubicin (administration & dosage) Etoposide (administration & dosage) Female Hematopoietic Stem Cell Transplantation Humans Leukemia, Myeloid, Acute (genetics, therapy) Mercaptopurine (administration & dosage) Mitoxantrone (administration & dosage) Neoplasm, Residual Oncogene Proteins (genetics) Oncogene Proteins, Fusion Polymerase Chain Reaction Prednisolone (administration & dosage) RNA, Messenger (analysis) Recombinant Fusion Proteins (genetics) Translocation, Genetic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!